Dexcom (DXCM) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue reached $1.004 billion, up 15% year-over-year (16% organic), driven by strong new customer additions and volume growth, but results fell short of expectations due to sales force realignment, faster rebate eligibility, and channel mix shifts.

• U.S. revenue grew 19% to $731.9 million, while international revenue grew 7% to $272.4 million (10% organic); DME channel underperformed, and U.S. revenue per customer declined due to increased rebate eligibility and channel shift.

• Product portfolio expanded with G7 direct-to-Apple Watch connectivity, Dexcom ONE+ launch in 18 markets, and upcoming Stelo OTC product targeting non-insulin users; expanded coverage in France for type 2 diabetes on basal insulin.

• New ICD-10 codes for hypoglycemia and expanded coverage in France support future growth; company continues to invest in R&D and global expansion.

• Board authorized a $750 million share repurchase program, reflecting confidence in long-term growth.

Financial highlights

• Q2 2024 worldwide revenue was $1.004 billion, up 15% year-over-year (16% organic); U.S. revenue grew 19% to $731.9 million, and international revenue grew 7% to $272.4 million.

• Non-GAAP gross profit was $638.1 million (63.5% margin), flat year-over-year; GAAP gross profit was $626.7 million (62.4% margin).

• Non-GAAP operating income was $195.4 million (19.5% margin), up from $158.4 million (18.2%); GAAP operating income was $158.0 million (15.7% margin).

• Adjusted EBITDA was $283.9 million (28.3% margin); non-GAAP net income was $174.3 million ($0.43 per share); GAAP net income was $143.5 million ($0.35 per share).

• Cash, cash equivalents, and marketable securities totaled $3.12 billion at quarter end.

Outlook and guidance

• Full-year 2024 revenue guidance lowered to $4.00–$4.05 billion (11%–13% organic growth); Q3 revenue expected between $975 million and $1 billion.

• Non-GAAP gross margin guidance reduced to ~63%; operating margin and adjusted EBITDA margin maintained at ~20% and ~29%.

• Global active customer base estimated at 2.5–2.6 million, with growth decelerating; 2025 long-range plan remains valid but likely at lower end of range.

• Management expects continued revenue growth driven by increased CGM adoption and new market expansion; significant capital expenditures planned for manufacturing capacity.

• Existing liquidity and cash flow from operations expected to fund operations and strategic initiatives for at least the next 12 months.